(RTTNews) – Johnson-Johnson (JNJ) fitness care Corporate (JNJ) company announced Thursday that its number one candidate vaccine is protective against infection with SARS-CoV-2, the guilty COVID-19 virus, with a single dose. preclinical studies.
The data, published in Nature, show that the experimental adenovirus vaccine based on the serotype 26 (Ad26) vector developed an immune response, as demonstrated through “neutralizing antibodies”, which effectively prevent additional infection and offer total or near total lung coverage opposed to the virus in non-human primates (PSNs) in the preclinical study.
Based on the robustness of the data, a first human clinical trial of the Ad26.VOC2.S candidate vaccine in healthy volunteers has now begun in the United States and Belgium.
The Janssen COVID-19 clinical trial program, which adds the Phase 1/2a clinical trial and the Phase 3 clinical trial program, will compare one- and two-dose Ad26 regimens. COV2. S in parallel studies.